{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:27:08Z","timestamp":1794014828834,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Lytix Biopharma AS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13058-018-1092-x","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T10:01:44Z","timestamp":1548237704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7440-4265","authenticated-orcid":false,"given":"Ketil A.","family":"Camilio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brynjar","family":"Mauseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Waagene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kvalheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Rekdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldur","family":"Sveinbj\u00f8rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild M.","family":"M\u00e6landsmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"issue":"1","key":"1092_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"10087","key":"1092_CR2","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","volume":"389","author":"C Denkert","year":"2017","unstructured":"Denkert C, et al. Molecular alterations in triple-negative breast cancer\u2014the road to new treatment strategies. Lancet. 2017;389(10087):2430\u201342.","journal-title":"Lancet"},{"issue":"4","key":"1092_CR3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ajpath.2013.05.033","volume":"183","author":"O Engebraaten","year":"2013","unstructured":"Engebraaten O, Vollan HKM, B\u00f8rresen-Dale A-L. Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol. 2013;183(4):1064\u201374.","journal-title":"Am J Pathol"},{"issue":"12","key":"1092_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40137-017-0194-1","volume":"5","author":"AD Williams","year":"2017","unstructured":"Williams AD, et al. Immunotherapy for breast cancer: current and future strategies. Curr Surg Rep. 2017;5(12):31.","journal-title":"Curr Surg Rep"},{"issue":"15","key":"1092_CR5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","volume":"29","author":"SMA Mahmoud","year":"2011","unstructured":"Mahmoud SMA, et al. Tumor-Infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949\u201355.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1092_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","volume":"24","author":"LA Emens","year":"2018","unstructured":"Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24(3):511\u201320.","journal-title":"Clin Cancer Res"},{"issue":"6870","key":"1092_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389\u201395.","journal-title":"Nature"},{"issue":"1\u20132","key":"1092_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0005-2736(99)00200-X","volume":"1462","author":"Y Shai","year":"1999","unstructured":"Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by \u03b1-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta. 1999;1462(1\u20132):55\u201370.","journal-title":"Biochim Biophys Acta"},{"issue":"Supplement C","key":"1092_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.peptides.2016.07.007","volume":"84","author":"R Domalaon","year":"2016","unstructured":"Domalaon R, et al. Ultrashort cationic lipopeptides and lipopeptoids: evaluation and mechanistic insights against epithelial cancer cells. Peptides. 2016;84(Supplement C):58\u201367.","journal-title":"Peptides"},{"key":"1092_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fchem.2017.00005","volume":"5","author":"MR Fel\u00edcio","year":"2017","unstructured":"Fel\u00edcio MR, et al. Peptides with dual antimicrobial and anticancer activities. Front Chem. 2017;5:5.","journal-title":"Front Chem"},{"key":"1092_CR11","first-page":"294","volume":"4","author":"D Gaspar","year":"2013","unstructured":"Gaspar D, Veiga AS, Castanho MARB. From antimicrobial to anticancer peptides. Rev Front Microbiol. 2013;4:294.","journal-title":"Rev Front Microbiol"},{"issue":"42","key":"1092_CR12","doi-asserted-by":"publisher","first-page":"71817","DOI":"10.18632\/oncotarget.17823","volume":"8","author":"S Riedl","year":"2017","unstructured":"Riedl S, et al. In vitro and in vivo cytotoxic activity of human lactoferricin derived antitumor peptide R-DIM-P-LF11-334 on human malignant melanoma. Oncotarget. 2017;8(42):71817\u201332.","journal-title":"Oncotarget"},{"issue":"8","key":"1092_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.chemphyslip.2011.09.004","volume":"164","author":"S Riedl","year":"2011","unstructured":"Riedl S, Zweytick D, Lohner K. Membrane-active host defense peptides - challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids. 2011;164(8):766\u201381.","journal-title":"Chem Phys Lipids"},{"issue":"1\u20133","key":"1092_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejphar.2009.08.043","volume":"625","author":"F Schweizer","year":"2009","unstructured":"Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol. 2009;625(1\u20133):190\u20134.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1092_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2014.05.002","volume":"351","author":"D Wu","year":"2014","unstructured":"Wu D, et al. Peptide-based cancer therapy: opportunity and challenge. Cancer Lett. 2014;351(1):13\u201322.","journal-title":"Cancer Lett"},{"key":"1092_CR16","doi-asserted-by":"publisher","first-page":"e29181","DOI":"10.4161\/onci.29181","volume":"3","author":"KA Camilio","year":"2014","unstructured":"Camilio KA, Rekdal \u00d8, Sveinbj\u00f6rnsson B. LTX-315 (Oncopore\u2122): A short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology. 2014;3:e29181.","journal-title":"Oncoimmunology"},{"issue":"7","key":"1092_CR17","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1021\/acs.jmedchem.5b02025","volume":"59","author":"BE Haug","year":"2016","unstructured":"Haug BE, et al. Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptide. J Med Chem. 2016;59(7):2918\u201327.","journal-title":"J Med Chem"},{"issue":"33","key":"1092_CR18","doi-asserted-by":"publisher","first-page":"34910","DOI":"10.18632\/oncotarget.5308","volume":"6","author":"L-M Eike","year":"2015","unstructured":"Eike L-M, et al. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget. 2015;6(33):34910\u201323.","journal-title":"Oncotarget"},{"issue":"21","key":"1092_CR19","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1080\/15384101.2015.1093710","volume":"14","author":"S Forveille","year":"2015","unstructured":"Forveille S, et al. The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle. 2015;14(21):3506\u201312.","journal-title":"Cell Cycle"},{"issue":"29","key":"1092_CR20","doi-asserted-by":"publisher","first-page":"26599","DOI":"10.18632\/oncotarget.5613","volume":"6","author":"H Zhou","year":"2015","unstructured":"Zhou H, et al. The oncolytic peptide LTX-315 kills cancer cells through Bax\/Bak-regulated mitochondrial membrane permeabilization. Oncotarget. 2015;6(29):26599\u2013614.","journal-title":"Oncotarget"},{"issue":"3","key":"1092_CR21","doi-asserted-by":"publisher","first-page":"e2134","DOI":"10.1038\/cddis.2016.47","volume":"7","author":"H Zhou","year":"2016","unstructured":"Zhou H, et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis. 2016;7(3):e2134.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1092_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00262-014-1540-0","volume":"63","author":"KA Camilio","year":"2014","unstructured":"Camilio KA, et al. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother. 2014;63(6):601\u201313.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"1092_CR23","doi-asserted-by":"publisher","first-page":"e1338236","DOI":"10.1080\/2162402X.2017.1338236","volume":"6","author":"J Nestvold","year":"2017","unstructured":"Nestvold J, et al. Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. Oncoimmunology. 2017;6(8):e1338236.","journal-title":"Oncoimmunology"},{"issue":"6","key":"1092_CR24","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/cdd.2016.35","volume":"23","author":"T Yamazaki","year":"2016","unstructured":"Yamazaki T, et al. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ. 2016;23(6):1004\u201315.","journal-title":"Cell Death Differ"},{"issue":"5","key":"1092_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1158\/2326-6066.CIR-16-0048","volume":"4","author":"R Abu Eid","year":"2016","unstructured":"Abu Eid R, et al. Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed. Cancer Immunol Res. 2016;4(5):377\u201382.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1092_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/erc.1.00671","volume":"12","author":"LA Emens","year":"2005","unstructured":"Emens LA, Reilly RT, Jaffee EM. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer. 2005;12(1):1\u201317.","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"1092_CR27","doi-asserted-by":"publisher","first-page":"e27058","DOI":"10.4161\/onci.27058","volume":"2","author":"H Sheng Sow","year":"2013","unstructured":"Sheng Sow H, Mattarollo SR. Combining low-dose or metronomic chemotherapy with anticancer vaccines: a therapeutic opportunity for lymphomas. Oncoimmunology. 2013;2(12):e27058.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1092_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","volume":"74","author":"D Alizadeh","year":"2014","unstructured":"Alizadeh D, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014;74(1):104\u201318.","journal-title":"Cancer Res"},{"issue":"5","key":"1092_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436\u201343.","journal-title":"Cancer Immunol Res"},{"key":"1092_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","volume":"419","author":"J Wu","year":"2018","unstructured":"Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210\u201321.","journal-title":"Cancer Lett"},{"key":"1092_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1092_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/cts.12391","volume":"9","author":"KM Morrissey","year":"2016","unstructured":"Morrissey KM, et al. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin Transl Sci. 2016;9(2):89\u2013104.","journal-title":"Clin Transl Sci"},{"issue":"12","key":"1092_CR33","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.4155\/fmc-2017-0088","volume":"9","author":"B Sveinbj\u00f8rnsson","year":"2017","unstructured":"Sveinbj\u00f8rnsson B, et al. LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment. Future Med Chem. 2017;9(12):1339\u201344.","journal-title":"Future Med Chem"},{"issue":"5","key":"1092_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/icb.1997.68","volume":"75","author":"JG Altin","year":"1997","unstructured":"Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell activation. Immunol Cell Biol. 1997;75(5):430\u201345.","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"1092_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.21147\/j.issn.1000-9604.2018.02.02","volume":"30","author":"Y Li","year":"2018","unstructured":"Li Y, Sun R. Tumor immunotherapy: new aspects of natural killer cells. Chin J Cancer Res. 2018;30(2):173\u201396.","journal-title":"Chin J Cancer Res"},{"issue":"5","key":"1092_CR36","first-page":"413","volume":"23","author":"S Ostrand-Rosenberg","year":"2005","unstructured":"Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Investig. 2005;23(5):413\u20139.","journal-title":"Cancer Investig"},{"issue":"1","key":"1092_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/eji.201343718","volume":"44","author":"SE Church","year":"2014","unstructured":"Church SE, et al. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol. 2014;44(1):69\u201379.","journal-title":"Eur J Immunol"},{"key":"1092_CR38","doi-asserted-by":"publisher","first-page":"14896","DOI":"10.1038\/srep14896","volume":"5","author":"J Matsuzaki","year":"2015","unstructured":"Matsuzaki J, et al. Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep. 2015;5:14896.","journal-title":"Sci Rep"},{"issue":"4","key":"1092_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1051\/medsci\/20143004020","volume":"30","author":"J Galon","year":"2014","unstructured":"Galon J, et al. Microenvironnement immunitaire et cancer. Med Sci (Paris). 2014;30(4):439\u201344.","journal-title":"Med Sci (Paris)"},{"issue":"3","key":"1092_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3626","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, et al. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11(3):215\u201333.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1092_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51\u201372.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"1092_CR42","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/0008-5472.CAN-09-3566","volume":"70","author":"L Aymeric","year":"2010","unstructured":"Aymeric L, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010;70(3):855\u20138.","journal-title":"Cancer Res"},{"key":"1092_CR43","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1084\/jem.20151665","volume":"213","author":"T-S Chan","year":"2016","unstructured":"Chan T-S, et al. Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. J Exp Med. 2016;213:2967.","journal-title":"J Exp Med"},{"issue":"1","key":"1092_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105\u201313.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1092_CR45","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin With doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860\u20137.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1092-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-018-1092-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1092-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T20:22:35Z","timestamp":1579638155000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-018-1092-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1186\/s13058-018-1092-x","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"3 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed were approved by the Experimental Animal Board under the Ministry of Agriculture of Norway and in compliance with The European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes. The manuscript does not contain any individual person\u2019s data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors approved of the manuscript and consented to its publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"\u00d8ystein Rekdal, Baldur Sveinbj\u00f8rnsson and Ketil Andr\u00e9 Camilio are employees and shareholders in Lytix Biopharma AS.\u00a0Brynjar Mauseth in an employee in Lytix Biopharma AS. The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"9"}}